CNS2024

Chronic Inflammatory Demyelinating Polyneuropathy: Pathophysiology, Diagnosis, and New and Emerging Treatment Options

Saturday, November 2nd, 2024 from 5:00pm – 6:00pm PDT

Name:*

First NameLast Name

Credentials:

State Licensed to Practice in:

Email:*

example@example.com

a. CSF protein is elevated, numbness and pain are present in the hands and feet, and axon loss is present on nerve conduction studiesb. Numbness is present in the feet, balance is unsteady, and nerve conduction studies show demyelinating changesc. Weakness and numbness are present in the arms and legs, and nerve conduction studies show demyelinating changesd. Numbness is present in the arms and legs, nerve conduction studies show axonal changes, and a patient reports feeling better after treatment with IVIG

a. Likely involves IgG antibodies, however no pathogenic antibody can be demonstrated in most patientsb. Is driven by a combination of T cell activation and targeted antibodies, which can be confirmed in most patientsc. Does not involve activation of the complement cascade in most patientsd. Is usually triggered by an external event, such as an infection

a. Patients were rarely found to not have CIDP by the adjudication panelb. Before entering Stage A open label, only patients that were treatment naïve or off treatments needed to demonstrate response to standard therapies (such as IVIG or corticosteroids) before entering Stage Ac. In Stage A, efgartigimod was administered subcutaneously once per week, but in Stage B, administration was every 2nd or 3rd week depending on clinical outcomesd. Most patients improved in the open label Stage A portion of the study and did not relapse in the Stage B randomized portion of the trial

Please rate the extent to which this activity met the following objectives:

Rows	Poor	Fair	Good	Very Good	Excellent
Review the pathophysiology and disease burden of CIDP, the role of IgG autoantibodies, accurate patient identification and diagnosis, and the limitations of current treatments.
Analyze recent clinical trial data on new and emerging biologic treatments for CIDP and be prepared to contextualize these data into their practices.
Develop individualized treatment plans for CIDP based on patient prognosis, a review of treatment options, an assessment of safety, familiarity with current treatment guidelines, and shared decision making.

Please provide us with feedback regarding your experience at the activity:

Rows	Poor	Fair	Good	Very Good	Excellent
Overall Program
Content
Usefulness

Please rate the faculty on his overall teaching ability:

Rows	Poor	Fair	Good	Very Good	Excellent
Perry B. Shieh, MD

YesNo

If no, please explain:

YesNoN/A

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team

What factors beyond clinical care that effect the health of your patients does your team experience?

courseTitle

credit-amount

Overall Activity Feedback